Nagaileben Nine-Month Operating Profit Dips 3.5% to ¥2.81bn on Flat Sales; Keeps Double-Digit Full-Year Growth Target

For the nine months to May 31, 2026, Japan's leading medical-apparel maker reported revenue of ¥13.27 billion (−0.7%) and operating profit of ¥2.81 billion (−3.5%), yet it reaffirmed full-year FY8/2026 guidance calling for a 12.3% rise in operating profit to ¥4.03 billion.

Nagaileben medical apparel and healthcare uniforms Nagaileben Co., Ltd. · TSE

Nagaileben Co., Ltd. (TSE: 7447), the Tokyo-based market leader in medical and healthcare apparel — white coats, nursing wear and surgical scrubs — reported a softer nine months for its fiscal year ending August 2026 (September 1, 2025–May 31, 2026) under Japanese GAAP. Cumulative revenue edged down 0.7% to ¥13.27 billion and operating profit fell 3.5% to ¥2.81 billion, while ordinary profit slipped 1.2% to ¥2.96 billion and net profit attributable to owners declined 1.0% to ¥2.05 billion. Basic EPS was ¥67.86, up from ¥66.53 a year earlier.

Resilient margins and a debt-free balance sheet

Despite the modest top-line dip, profitability stayed exceptionally high, with an operating margin above 21%. The company's balance sheet remains among the strongest on the Tokyo market: total assets of ¥42.73 billion, net assets of ¥39.42 billion and an equity ratio of 92.3% (versus 92.5% a year earlier), reflecting a virtually debt-free capital structure. Comprehensive income rose 2.6% to ¥2.12 billion.

Dividend reset after a prior-year commemorative payout

For FY8/2026 Nagaileben plans an annual dividend of ¥70.00 per share, paid as a single year-end dividend. That compares with ¥100.00 a year earlier, but the prior-year figure included a ¥40.00 commemorative dividend on top of a ¥60.00 ordinary payout, so the underlying ordinary dividend is being lifted from ¥60 toward ¥70.

Full-year outlook keeps double-digit growth

Management left full-year FY8/2026 guidance unchanged, projecting revenue of ¥18.00 billion (+6.0%), operating profit of ¥4.03 billion (+12.3%), ordinary profit of ¥4.20 billion (+13.3%) and net profit of ¥2.90 billion (+12.7%), for EPS of ¥96.54. With nine-month operating profit at ¥2.81 billion, the target implies a strong fourth quarter (June–August), historically the company's busiest period for healthcare-uniform orders.

Nagaileben — 9M FY8/2026 Key Financials (J-GAAP, consolidated)
Metric9M FY8/269M FY8/25YoY
Revenue (¥bn)13.2713.37−0.7%
Operating profit (¥bn)2.812.92−3.5%
Ordinary profit (¥bn)2.963.00−1.2%
Net profit attrib. (¥bn)2.052.07−1.0%
EPS (¥)67.8666.53+2.0%
Equity ratio92.3%92.5%−0.2pp
FY8/26 OP guidance (¥bn)4.033.58+12.3%

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.